Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 29;5:61. doi: 10.1038/s41698-021-00192-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Representative immunohistochemistry images of PTX3 expression in pancreatic cancer tissue after ATRA or vehicle treatment in KPC mouse model. Scale bar = 50 μm. b Serum vitamin A levels in patients with PDAC (n = 10) in comparison with healthy controls (n = 16), Mann–Whitney U test, **P < 0.01, summary data expressed as median and interquartile range. c Correlation plot between serum vitamin A and PTX3 levels in patients with PDAC and healthy subjects. Pearson r = −0.44, (95% CI: −0.71 to −0.07), p = 0.024). d Serum PTX3 levels in a cohort of patients with PDAC from SCALOP clinical trial. e Serum PTX3 levels in patients on STARPAC clinical trial as measure before (pre) and 5 h after (post) giving the first ATRA dose (Cycle 1, Day 1). Comparison are made between those patients who progressed (P) and not progressed (NP = stable disease and partial response), Mann–Whitney U-test. *P < 0.05, n.s = not significant, summary data expressed as median and interquartile range.